

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshiaki Sai, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com/>

Update Regarding Kitasato Daiichi Sankyo Vaccine's Influenza HA Vaccine Supply Plan

Tokyo, Japan (October 31, 2011) – Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) today announced that the remaining approx. 2,400,000 doses (out of approx. 4,760,000) of its Kitasato Daiichi Sankyo influenza HA vaccine and Kitasato Daiichi Sankyo influenza HA vaccine syringe produced by its subsidiary, Kitasato Daiichi Sankyo Vaccine, which had been undergoing intensive quality tests at the time of the September 22 announcement regarding a change in the supply plan have now completed testing and been found to be in line with Daiichi Sankyo's internal quality specifications.

Shipments of the lots of these remaining doses have gradually begun from the end of October following government certification.

Furthermore, Kitasato Daiichi Sankyo Vaccine is making every effort to increase production with the goal of supplying approx. 1,200,000 additional doses from the beginning of January 2012.

Once again, Daiichi Sankyo offers its deepest apologies for the disruption in the supply of influenza HA vaccine. Moreover, by continuing to work closely with the authorities, Daiichi Sankyo will do its utmost to ensure a stable supply of its vaccine products to all healthcare professionals and other persons who are waiting for this vaccine in Japan.